Automated Pen Injectors Improve User Experience for GLP-1 Receptor Agonist Delivery

GLP-1 Receptor Agonists (GLP-1 RAs), such as semaglutide and tirzepatide, are crucial for managing chronic conditions like type 2 diabetes and obesity, often requiring regular self-injection. The design and usability of these pen injectors significantly influence patient adherence, safety, and overall treatment experience. This study addresses the critical need to compare user performance, safety, and preference between traditional manual pen injectors and newer, partially automated designs for GLP-1 RA delivery.

The partially automated pen injector significantly reduced critical errors compared to the manual pen, demonstrating a 65% reduction in errors (e.g., incorrect dose dialing, incomplete injection) (p<0.001). Users of the automated pen reported 2.3-fold higher overall satisfaction scores and perceived 30% less injection pain (p<0.01). Injection completion time was also 15% faster with the automated device (p<0.05). The most significant finding was that 92% of participants expressed a strong preference for the partially automated pen, citing its ease of use and reduced anxiety associated with self-administration. Specifically, zero critical errors related to dose setting were observed with the automated pen, compared to 18 errors with the manual pen.